- Home
- XFOR vs STTK Comparison
XFOR vs STTK Comparison
Compare XFOR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- STTK
- Stock Information
- Founded
- XFOR 2014
- STTK 2016
- Country
- XFOR United States
- STTK United States
- Employees
- XFOR N/A
- STTK N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- STTK Health Care
- Exchange
- XFOR Nasdaq
- STTK Nasdaq
- Market Cap
- XFOR 84.3M
- STTK 83.8M
- IPO Year
- XFOR N/A
- STTK 2020
- Fundamental
- Price
- XFOR $3.21
- STTK $2.14
- Analyst Decision
- XFOR Strong Buy
- STTK Hold
- Analyst Count
- XFOR 3
- STTK 6
- Target Price
- XFOR $34.17
- STTK $2.67
- AVG Volume (30 Days)
- XFOR 1.5M
- STTK 1.5M
- Earning Date
- XFOR 11-12-2025
- STTK 11-13-2025
- Dividend Yield
- XFOR N/A
- STTK N/A
- EPS Growth
- XFOR N/A
- STTK N/A
- EPS
- XFOR N/A
- STTK N/A
- Revenue
- XFOR $32,774,000.00
- STTK $2,997,000.00
- Revenue This Year
- XFOR $1,313.84
- STTK N/A
- Revenue Next Year
- XFOR N/A
- STTK N/A
- P/E Ratio
- XFOR N/A
- STTK N/A
- Revenue Growth
- XFOR 5721.31
- STTK N/A
- 52 Week Low
- XFOR $1.35
- STTK $0.69
- 52 Week High
- XFOR $26.83
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- XFOR 51.32
- STTK 58.93
- Support Level
- XFOR $3.08
- STTK N/A
- Resistance Level
- XFOR $3.79
- STTK $2.01
- Average True Range (ATR)
- XFOR 0.40
- STTK 0.21
- MACD
- XFOR -0.11
- STTK 0.01
- Stochastic Oscillator
- XFOR 16.92
- STTK 99.53
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.